News und Analysen

Abbott Laboratories (NYSE: ABT) announced its 2025 fourth-quarter and full-year results before the market opened on Thursday, Jan. 22, 2026. And its shares promptly plunged nearly 10%. As you

When you're talking about the biggest stock market stories of 2025, Nvidia (NASDAQ: NVDA) is a name that keeps coming up. The company has been one of the biggest winners of the artificial

The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain

Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) underperformed in 2025. Both companies encountered some issues, some of which may linger throughout this year.

However, these drugmakers

On January 23, Liberty Street Advisors disclosed a buy of 136,925 shares of Voyager Technologies (NYSE:VOYG), an estimated $3.71 million trade based on quarterly average pricing.

According to its

Some investors believe the market is currently overvalued. Hype and optimistic expectations, especially for artificial intelligence (AI) stocks, are baked into equity prices, or so the argument

ImmunityBio (NASDAQ:IBRX), an immunity-focused biotech, closed Friday’s session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.

Trading

There are few better, simpler, and more accessible ways to accumulate wealth over the long term than buying and holding shares of outstanding companies. And although it can be challenging to find

On January 22, 2026, Premier Path Wealth Partners, LLC disclosed a purchase of 64,073 shares of iShares Trust - iShares MSCI ACWI ex U.S. ETF (NASDAQ:ACWX), an estimated $4.25 million trade based on

If you had only $30 to spend on a single share of a company, which one would you choose? Although price and value aren't the same thing on equity markets, the best stocks tend to attract enough

Although investors have been told that spending on artificial intelligence (AI) is going to ramp up again in 2026, some are getting a bit weary of the AI trade. However, they must realize that this

Zoetis (NYSE: ZTS) and Regeneron Pharmaceuticals (NASDAQ: REGN) are two healthcare leaders that have lagged broader equities over the past 12 months, as both encountered headwinds that led to

It's been a less-than-thrilling past few months for investors in Palantir Technologies (NASDAQ: PLTR), but understandably so. Shares of the artificial intelligence software powerhouse remain

For the first 10 years of its publicly traded life, leading animal healthcare stock Zoetis (NYSE: ZTS) easily outpaced the S&P 500, rising 480% and doubling the index's total returns. However, since

It's been a rough past 12 months for UnitedHealth Group (NYSE: UNH), with the stock price down nearly 34% (through Jan. 20). This is not-so-great news for a company that's had its fair share of

If you're a retiree, you may be concerned about how safe it is to invest in the stock market right now. Valuations are high, economic conditions are questionable, and it's getting more difficult to

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to

There's nothing quite like making money while you sleep. And investing in dividend stocks is a great way to do that. However, with so many dividend payers, it can be hard to know which one to pick.

The market had no love for Sarepta Therapeutics (NASDAQ: SRPT) and Teladoc Health (NYSE: TDOC) last year, as both companies lagged broader equities and lost significant market value. This might make

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what to do

Last year was a challenging one for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech. The company made little clinical progress and, in fact, one of the major data readouts it released was not

For the last three years, the S&P 500 index has generated abnormally high returns thanks to absurd levels of demand for artificial intelligence (AI). In particular, the technology and infrastructure

Explore the exciting world of Insulet (NASDAQ: PODD) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market